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vaccine candidate aminopeptidase H11 using the
free-living nematode Caenorhabditis elegans
Brett Roberts1, Aristotelis Antonopoulos2, Stuart M Haslam2, Alison J Dicker3, Tom N McNeilly3,
Stephanie L Johnston1, Anne Dell2, David P Knox3 and Collette Britton1*Abstract
With the problem of parasitic nematode drug resistance increasing, vaccine development offers an alternative
sustainable control approach. For some parasitic nematodes, native extracts enriched for specific proteins are highly
protective. However, recombinant forms of these proteins have failed to replicate this protection. This is thought to
be due to differences in glycosylation and/or conformation between native and recombinant proteins. We have
exploited the free-living nematode Caenorhabditis elegans to examine its suitability as an alternative system for
recombinant expression of parasitic nematode vaccine candidates. We focussed on Haemonchus contortus
aminopeptidase H11 glycoprotein, which is enriched in a gut membrane fraction capable of inducing significant
protection against this important ovine gastrointestinal nematode. We show that H. contortus H11 expressed in
C. elegans is enzymatically active and MALDI mass spectrometry identifies similar di- and tri-fucosylated structures
to those on native H11, with fucose at the 3- and/or 6-positions of the proximal GlcNAc. Some glycan structural
differences were observed, such as lack of LDNF. Serum antibody to native H11 binds to C. elegans recombinant
H11 and most of the antibody to rH11 or native H11 is directed to glycan moieties. Despite these similarities, no
reduction in worm burden or faecal egg count was observed following immunisation of sheep with C. elegans-
expressed recombinant H11 protein. The findings suggest that the di- and tri-fucosylated N-glycans expressed on
rH11 do not contribute to the protective effect of H11 and that additional components present in native
H11-enriched extract are likely required for enhancing the antibody response necessary for protection.Introduction
Parasitic nematode infections of livestock are responsible
for significant economic losses and welfare concerns glo-
bally. Control currently relies on the use of anthelmintic
drugs, however the widespread problem of parasite an-
thelmintic resistance means that this approach is becom-
ing unsustainable [1,2]. The recent introduction of a new
class of anthelmintic, the aminoacetonitrile derivatives
(ADDs; monepantel), offers an alternative [3]. However
resistance to this new drug class has already been re-
ported in nematodes of sheep and goats in less than
2 years of use [4]. Alternative, sustainable control measures,
such as vaccination and improved pasture management,* Correspondence: Collette.Britton@glasgow.ac.uk
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reproduction in any medium, provided the orare urgently needed. Significant protection against livestock
nematode infections has been achieved following vaccin-
ation with native protein extracts, demonstrating that vac-
cination is feasible [5-7]. However, from a production
and cost perspective, the long term aim is to develop
molecularly defined vaccines amenable to commercial
development, without the need for native parasite ma-
terial and the associated ethical and safety concerns.
Currently there is no molecularly defined vaccine avail-
able for any parasitic nematode.
A significant amount of data is available from vaccine
trials against the blood-feeding gastrointestinal (GI) nema-
tode of sheep and goats, Haemonchus contortus. Native
proteins extracted from the adult parasite gut or from
excretory-secretory (ES) products are capable of indu-
cing high levels of protection (up to 90% reduction in
faecal egg counts (FEC) and 75% reduction in worml Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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binding glycoprotein complex termed H-gal-GP enriched
for metallo and aspartic proteases, a thiol-binding fraction
enriched for cysteine proteases, and a Concanavalin A
binding fraction enriched for aminopeptidase H11. How-
ever, attempts to mimic the protective effects of these
native extracts using recombinant forms of the enriched
proteases expressed in bacteria, yeast or insect cells have
proved unsuccessful [6,8]. Protection studies against the
cattle GI nematode Ostertagia ostertagi have similarly
demonstrated significant reductions in egg output using
an ES fraction highly enriched for two activation-
associated secreted proteins (ASP-1 and ASP-2) [9].
However, vaccination with baculovirus-expressed ASP-1
protein failed to induce any protection [10]. There has
been much speculation as to why recombinant parasitic
nematode proteins fail to induce protective immunity.
Possible explanations include incorrect folding, lack of
glycosylation of bacterially-expressed proteins, inappropri-
ate glycosylation of yeast or insect-expressed proteins,
induction of lower avidity antibodies or, alternatively,
that the dominant proteins identified in protective native
fractions are not solely responsible for protection [8].
Gene rescue studies have previously demonstrated that
parasite proteins can be expressed in a biologically active
form in the free-living nematode C. elegans [11-14]. How-
ever, expression of parasite proteins with complex post-
translational modifications has not been tested in C. elegans.
In this study we focus on H. contortus H11 aminopeptidase,
due to the high level of protection achieved with native
gut extracts enriched for H11 and the unusual glycosyl-
ation identified on the native protein. Previous mass
spectrometric analysis identified unusual fucosylated
modifications on native H11, including core α1-3 and
α1-6 fucosylation [15]. The former is not found on
mammalian glycans and has been shown to be highly
antigenic when present on plant and insect glycopro-
teins [16]. The core α1-3 Fuc epitope is recognised by
IgE antibody from H. contortus infected sheep and is
speculated to contribute to the induction of a Th2 re-
sponse [17]. Core α1-3 and α1-6 fucosylation structures
have also been identified on C. elegans glycoproteins
(though it should be noted that these are often addition-
ally substituted with galactose residues) [18-20] and have
been shown to induce Th2 type immune responses in
mice, similar to parasite glycans [21]. α1-3 and α1-6 fuco-
syltransferases have been characterised from C. elegans
[22], indicating that glycosylation pathways and the
resulting glycan modifications are similar in free-living
and parasitic nematodes. C. elegans may therefore present
a suitable system for expression and analysis of parasite
glycans as important immunogens. Here we express
recombinant H. contortus H11 protein in C. elegans
and characterise the glycosylation pattern, enzymaticactivity and antibody recognition of native and recom-
binant protein. Our findings have important relevance
to expression of other nematode vaccine candidates and
requirements for protective immunity.
Materials and methods
Identification of genomic location of H. contortus H11 genes
The available H. contortus genome data (strain MHco3
(ISE)) [23,24] was searched by tBLASTn using amino acid
sequences of all available H11 isoforms. This identified
a number of overlapping scaffolds encoding known
H11 sequences and identified a novel sequence, named
H11-5 [GenBank Accession number KF381362]. Tandem
arrangement of H11 genes was indicated by scaffold
sequence analysis and confirmed experimentally by PCR
on genomic DNA, extracted by standard method from
H. contortus adult worms ((MHco3(ISE) strain), using
DNA primers designed to the 5′ and 3′ ends of each H11
gene coding sequence. All primer sequences are available
on request.
RNA extraction from H. contortus and semi-quantitative
RT-PCR
Total RNA was extracted from H. contortus adult worms
using an RNAeasy kit (Qiagen) after grinding the worms
in liquid nitrogen. Reverse Transcription was performed
using an AffinityScript cDNA Synthesis kit (Stratagene)
as per manufacturer’s instructions. Semi-quantitative
RT-PCR was carried out as described previously [25],
using constitutively expressed superoxide dismutase gene
(Hc-sod-1) as a reference [26]. Relative levels of each H11
gene were determined using ImageJ [27].
Generation of H. contortus H11 expression constructs
An expression cassette containing 1.76 kb of promoter
sequence of C. elegans cathepsin L protease gene cpl-1
and 500 bp of Ce-cpl-1 3′ UTR was generated in the
TOPO 2.1 vector (Invitrogen) by standard cloning methods
as previously described [12]. The cDNA region encoding
the putative signal peptide sequence (first 29 amino acids)
of the H. contortus Hmcp-6 gene (accession number
GQ223792) was inserted between the cloned Ce-cpl-1
promoter and 3′ UTR regions. The H. contortus H11
coding sequence for each isoform (approximately 2.9 kb)
was inserted into the expression cassette between the
Hmcp-6 signal peptide-encoding region and Ce-cpl-1
3′UTR using Nru I and Xho I restriction sites at these
positions. The H11 coding regions were amplified using
PfuUltra II Fusion HS DNA Polymerase (Stratagene)
and H. contortus adult worm cDNA as template. The
5′ primers were designed to amplify downstream of the
encoded N-terminal transmembrane domain (35 amino
acids) of each H11 gene. The 3′ primers contained
Afe I sites to allow for the insertion of a 10 amino
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synthetic intron (SI) was inserted into available blunt
end restriction sites within the H11 genes to improve
transgene expression [28]. A diagrammatic representa-
tion of the final H11 expression construct is shown in
Additional file 1. The integrity of all constructs was veri-
fied by automated DNA sequencing (Eurofins MWG).C. elegans transgenesis
Each H11 gene expression construct was microinjected
into the gonads of C. elegans adult hermaphrodite worms
of strain DR96 (unc-76(e911)) as simple free arrays at a
final concentration of 10 μg/mL, together with the rescue
marker plasmid p76-16B [29] at a final concentration of
10 μg/mL and 1 kb ladder DNA (100 μg/mL) [30]. Trans-
genic animals were selected on the basis of reversion from
an uncoordinated (unc) to wild-type phenotype.Culture of C. elegans transgenic worms and protein
purification
C. elegans worms transformed with the H11 expression
constructs were grown on 9 cm diameter peptone rich
plates seeded with N22 bacteria [31] for approximately
seven days. Worms were washed from the plates in
0.1 M NaCl and separated from bacteria by centrifugation
at 3000 rpm on a 60% (w/v) sucrose gradient. Worms were
collected from the upper phase and washed three times in
ice cold 0.1 M NaCl by centrifugation at 3000 rpm. The
worm pellet was resuspended in an equal volume of 1×
lysis buffer (50 mM NaPO4, 300 mM NaCl, 10 mM imid-
azole) and stored at −70 °C. After thawing on ice, the vol-
ume was made up to 10 mL with 1× lysis buffer. Worms
were sonicated for 10 cycles of 10 s on/20 s off on ice,
followed by homogenisation in a standard glass homogen-
iser. The worm extract was centrifuged at 13 000 rpm for
3 min and the cleared lysate collected and stored on ice.
The worm pellet was resuspended in 3 mL of 1× lysis buffer
and re-sonicated and homogenised. After centrifugation,
the lysates were pooled, added to 300 μL of HisPur Cobalt
Resin (ThermoScientific) and mixed gently on a roller at
4 °C for 2 h. The solution was loaded onto a 1 mL poly-
propylene column (Qiagen) and the resin washed with
4 mL lysis buffer, followed by 4 mL of lysis buffer contain-
ing 0.04 M imidazole. Bound protein was eluted with six
aliquots of 150 μL of 1× lysis buffer containing 0.125 M
imidazole. Eluted protein was dialysed against 1 × PBS using
Slide-a-Lyzer cassettes (Thermo Scientific) and the protein
concentration estimated using the Coomassie Protein Assay
Reagent (Thermo Scientific). Protein was analysed by
4-15% gradient SDS polyacrylamide gel electrophoresis
(SDS-PAGE; Bio-Rad minisystem) followed by Coomassie
staining (0.25%).Protein identification by mass spectrometry
A sample of C. elegans-expressed recombinant H11-4
(rH11-4) protein purified by cobalt chelation chromatog-
raphy was subjected to SDS-PAGE, stained with Coomassie
blue and the major band excised. Standard mass spectrom-
etry procedure was performed with in-gel trypsin digest,
extraction of tryptic peptides, fractionation by RP-HPLC
and online nano-electropsray tandem mass spectrometry
(MS). Data was searched against the National Center for
Biotechnology Information (NCBI) database using the
Mascot search engine (Proteomics Services, University
of Glasgow). Native H11 protein was extracted from
H. contortus adult worms (day 28) by solubilisation of a
PBS homogenate pellet in 1% thesit and purified using
Concanavalin A (Con A) sepharose (Sigma). Protein ex-
tract was separated on a 4-15% SDS-PAGE gel, stained
with Coomassie blue and the major band of approxi-
mately 110 kDa excised and subject to MS as described
above (Proteomics Unit, Moredun Research Institute).
SDS-PAGE and Western blotting
Protein samples were boiled for 5 min in an equal
volume of 2 × SDS-PAGE loading buffer containing 5%
β-mercaptoethanol and separated by 4-15% gradient
SDS-PAGE. Proteins were visualised with Coomassie
blue or western blotting carried out by transferring the
proteins onto PVDF membrane (Amersham). Blots
were probed with a variety of antibodies: mouse anti-
HIS (C-terminal) (Invitrogen; 1 in 4000 dilution), sheep
antiserum to native H11-enriched gut membrane extract
(1 in 2000 dilution), Con A-horseradish peroxidase (HRP;
Sigma L6397; 0.5 μg/mL), mouse IgA TEPC-15 antibody
(Sigma M1421, 1 in 2500 dilution) and sheep antiserum
raised to C. elegans-expressed recombinant H11 (1 in
2000 dilution). HRP-conjugated secondary antibodies were
routinely used at 1 in 10 000 dilution and binding de-
tected using the Enhanced Chemiluminscent (ECL)
system (GE Healthcare).
Site-directed mutagenesis of H. contortus H11-4
The three putative N-glycosylation sites of H11-4 (identi-
fied as described in [32]) were altered by site-directed
mutagenesis using the QuikChange Lightning Multi
Site-Directed Mutagenesis Kit (Stratagene) according to
the manufacturer’s instructions. Three gene specific primers
were used in which the codon for asparagine was altered
to that for glutamine. DNA sequencing confirmed alter-
ation of all three codons (Eurofins MWG).
Mild periodate treatment of H11 proteins
PVDF membrane containing native H11-enriched extract
or rH11-4 protein was washed with 30% isopropanol, 10%
acetic acid for 5 min, before being rinsed in 50 mM so-
dium acetate pH 4.5, 50 mM NaCl buffer. The following
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blot was incubated in the above buffer containing 10 mM
sodium metaperiodate for 1 h, rinsed 3 times in water
before being incubated in 20 mM Tris, pH 7.2, 150 mM
NaCl, 200 mM glycerol for 20 min. After rinsing 3 times
in 20 mM Tris, pH 7.2, 150 mM NaCl, the standard
immunoblotting protocol was followed [33].
Glycan analysis
A sample of rH11-4 protein was processed as previously
described [34]. Briefly, rH11-4 protein was subjected to
reduction in 4 M guanidine HCl (Pierce) containing
2 mg/mL dithiothreitol, carboxymethylation and trypsin
digestion, and the digested glycoprotein was purified by
C18-Sep-Pak (Waters Corp., Hertfordshire, UK). N-linked
glycans were released by peptide:N-glycosidase F (EC
3.5.1.52, Roche Applied Science) and peptide:N-glycosi-
dase A (EC 3.5.1.52, Roche Applied Science) digestions.
N-linked glycans were then permethylated using the
sodium hydroxide procedure, and finally, the permethy-
lated N-linked glycans were purified by C18-Sep-Pak. All
permethylated samples were dissolved in 10 μL of metha-
nol, and 1 μL of dissolved sample was premixed with 1 μL
of matrix (20 mg/mL 2,5-dihydroxybenzoic acid in 70%
(v/v) aqueous methanol). The mixture was then spotted
onto a target plate (2 × 0.5 μL), and dried under vacuum.
MS data were acquired using a Voyager-DE STR MALDI-
TOF (Applied Biosystems, Darmstadt, Germany). MS/MS
data were acquired using a 4800 MALDI-TOF/TOF
(Applied Biosystems) mass spectrometer. The collision
energy was set to either 1 or 2 kV, and argon was used
as collision gas. The 4700 calibration standard kit,
Calmix (Applied Biosystems), was used as the external
calibrant for the MS mode of both instruments, and
[Glu1] fibrinopeptide B human (Sigma) was used as
an external calibrant for the MS/MS mode of the
MALDI-TOF/TOF instrument.
The MS and MS/MS data were processed using Data
Explorer 4.9 Software (Applied Biosystems). The spectra
were subjected to manual assignment and annotation
with the aid of the glycobioinformatics tool, GlycoWork-
Bench [35]. The proposed assignments for the selected
peaks were based on 12C isotopic composition together
with knowledge of the biosynthetic pathways. The pro-
posed structures were then confirmed by data obtained
from MS/MS experiments.
Aminopeptidase activity assays
Aminopeptidase activity was determined by standard
assay using L-leucine p-nitroanilide substrate (L-Leu-pNA;
Sigma). Protein sample (500 ng/well) was mixed with
100 μL 50 mM NaPO4 buffer (pH5.5-7.5) and 10 μL
L-Leu-pNA (0.5 mM final concentration). The initial
and final absorbance (after 2 h at 37 °C and overnightincubation at room temperature) was determined at
405 nm using a Beckman DU530 spectrophotometer.
To test inhibitor sensitivity, assays were carried out as
above, but with pre-incubation for 10 min in amasta-
tin or bestatin (both at 10 μM final concentration)
prior to the addition of pNA substrate.
Vaccine trial
Six month old indoor housed, worm-free Suffolk-cross
lambs were allocated into groups of seven, balanced for
sex and weight. One group received three immunisations
(sub-cutaneously) of C. elegans-expressed rH11-1 and
rH11-4 protein (a combination of 10 μg of each protein)
or rH11-4 and rH11-5 co-expressed in C. elegans (20 μg
total protein) at three weekly intervals and were chal-
lenged with 5000 infective L3 stage H. contortus on the
day of the final immunisation (day 42). Vax Saponin
(Guiness Chemical Products Ltd) was used as adjuvant
at a final concentration of 1 mg/mL and the final vac-
cine volume was adjusted to 1 mL with 1× TBS. Blood
was sampled at weekly intervals and FEC monitored
three times weekly from day 14 after challenge until nec-
ropsy at day 35 when worm numbers were counted, as
previously described [36]. Control groups were injected
with 1 × TBS and adjuvant only or with 40 μg of native
gut membrane extract enriched for H11 plus adjuvant,
following the method of [37]. All experimental proce-
dures were approved by the Moredun Research Institute
Experiments and Ethics committee and carried out in
accordance with the Animals (Scientific Procedures) Act
of 1986.
ELISA
Microtitre plates were coated overnight at 4 °C with
1 μg/mL of a combination of rH11-1 and rH11-4 pro-
teins or rH11-4 and rH11-5 co-expressed proteins di-
luted in 50 mM bicarbonate buffer, pH 9.6. The avidity
of serum antibody from lambs vaccinated with native
H11-enriched extract or rH11 protein against the hom-
ologous protein was estimated using the thiocyanate
elution method [38], with the addition of 0-5 M KSCN
to all washes. Avidity was estimated as the concentra-
tion of KSCN which resulted in a 50% reduction in OD
value at a particular serum dilution (1/800). Mild sodium
periodate-treatment (final concentration 5 mM) was
performed after coating of protein to wells, as previ-
ously described [39].
Antibody isotype reactivity was determined using stand-
ard ELISA method with primary antibody at 1/50 dilution
and probing with mouse anti-ovine IgG (clone GT-34,
Sigma-Aldrich; 1/2500 dilution), IgM (clone VPM13,
Moredun Research Institute; 1/1000 dilution), IgE (clone
2 F1, Moredun Research Institute; 1/100 dilution) or IgA
(AbD Serotec clone K84 2 F9; 1/1000 dilution). Secondary
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(Sigma-Aldrich A2304, 1/1000).
Statistical analysis
Statistical analysis of the FEC and worm burden results
was carried out following the guidelines set out in [40]
and data analysed using Excel 2010.
Results
Developmental expression of H11 gene family
Genes encoding four different isoforms of H. contortus
H11 were previously identified (H11, H11-1, H11-2 and
H11-4) and in this study we identified a fifth isoform
(H11-5) from the available H. contortus genome data.
Analysis of overlapping H. contortus scaffolds, in addition
to performing PCR on H. contortus genomic DNA,
showed that all 5 isoforms are tandemly arranged in the
genome (Figure 1A). Our findings expand on previous
data [41], which showed linkage of H11-4 and H11
genes, and suggest that the H11 gene family has arisen
through recent duplication and divergence. The encoded
proteins share 62-75% amino acid identity, with the
zinc binding domain (HELAH) and exopeptidase motifA
B
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RT-PCR of the five H. contortus H11 genes in infective L3 larvae (striped bars) an
constitutively expressed control gene Hc-sod-1. Mean of triplicate PCRs is shown(GAMEN) characteristic of N-aminopeptidases highly
conserved in all isoforms (Additional file 2). All H11
proteins contain predicted N-glycosylation sites, as shown
in the amino acid sequence alignment in Additional file 1.
Semi-quantitative RT-PCR identified transcript for
all five isoforms in adult worms, with significantly lower
expression in infective L3 stage larvae (Figure 1B). Differ-
ent isoforms showed different patterns of expression,
with H11-1 the most abundant isoform in infective
L3 larvae, H11-4 the most abundant isoform in adult
worms and H11-5 only expressed in adult female
worms (not shown). Subsequent RNA seq data [23]
confirmed the male-specific expression of H11-5 and
identified significant enrichment of transcripts encod-
ing H11-4, H11 and H11-2 in H. contortus adult gut
tissue. All five H11 isoforms are present in native H11
protein extract, as indicated by MS peptide sequencing,
with more peptide matches found to H11-1 than to the
other isoforms (Mascott scores ranged from 390–5567).
Based on this data, H11-1, H11-4 and H11-5 were
selected for large-scale protein expression in C. elegans,
followed by glycan and enzymatic characterisation, and
vaccine testing.6.1
p)
scaffold 822.1
(109,415 bp)
11-4         H11         H11-2
H11-4 H115
ype
ntortus H11 isoforms. (A) H. contortus overlapping genomic scaffold
ate the direction of transcription from each scaffold. (B) Semi-quantitative
d in adult worms (blue bars). Expression of each gene is shown relative to
, with error bars showing the standard error of the mean.
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using C. elegans
H. contortus H11 isoforms were expressed in transgenic
C. elegans as soluble proteins by substituting the N-terminal
transmembrane domain with a short signal peptide se-
quence. Previous studies demonstrated that a soluble
form of native H11, in which the transmembrane do-
main was removed, was equally protective compared to
full-length H11 [8]. Coomassie staining and Western
blotting using antibody to the C-terminal His tag or
antiserum to native H11-enriched extract (nH11) con-
firmed that recombinant H11 protein (rH11) was the
major cobalt-binding protein in a PBS-soluble extract of
C. elegans mixed stage transgenic worms (Figure 2). Pre-
bleed serum prior to H11-extract immunisation showedAnti-His Anti-nH11CoomassierH11-4 
115kDa
Anti-His Anti-nH11CoomassierH11-1 
115kDa
Anti-His Anti-nH11CoomassierH11-5
115kDa
Figure 2 Expression and purification of recombinant H11-4,
H11-1 and H11-5 expressed in C. elegans. rH11 proteins purified
by cobalt chelation chromatography were separated by 4-15%
SDS-PAGE and stained with Coomassie blue or transferred to PVDF
membrane and probed with anti-His (C-terminal) antibody or
antiserum to native H11-enriched extract (Anti-nH11). Antiserum
from animals prior to H11-extract immunisation showed no reactivity
to rH11 isoforms.no reactivity. The identity of rH11 was also confirmed by
MS peptide sequencing. While characterisation focussed
on H11-1, H11-4 and H11-5, all 5 isoforms were able to
be expressed in recombinant form in C. elegans and anti-
serum raised to native H11-enriched extract recognised
all rH11 isoforms. For each rH11 protein, the yield was
approximately 70–100 μg purified protein per mL packed
volume of C. elegans transgenic worms.
Enzymatic activity of recombinant H11 proteins
expressed in C. elegans
Aminopeptidase activity of rH11 proteins expressed in
C. elegans was examined by standard aminopeptidase en-
zyme assay using L-leucine p-nitroanilide (pNA) as sub-
strate. H11 recombinant proteins were enzymatically
active, with rH11-4 and rH11-5 showing greater activity
than H11 and H11-1 isoforms (Figure 3). rH11-4 and
rH11-5 proteins co-expressed and purified from the
same C. elegans transgenic line (rH11-4/5) showed an
increase in aminopeptidase activity relative to singly-
expressed forms, which was consistent in all assays, and
suggests possible interaction and/or stablisation of these
isoforms (Figure 3A). H11-5 showed greater activity at
pH 5.5, while H11-4 was more active at pH 7.0, similar
to native H11-enriched extract. Aminopeptidase activity
of the rH11-4 and rH11-5 co-expressed proteins and
native H11-enriched extract was inhibited to a similar
degree by standard aminopeptidase inhibitors amastatin
and bestatin (60-70% reduction; Figure 3B). The activity
and inhibition observed suggested that the recombinant
H11 proteins were folded appropriately into active enzymes.
C. elegans-expressed rH11 protein is N-glycosylated
Native H. contortus H11 protein binds to Concanavalin
A lectin (Con A) [42] and previous mass-spectrometric
analysis identified N-glycans with highly fucosylated core
structures [15]. Interaction with Con A-HRP was exam-
ined by Western blotting, and showed strong binding to
native H11-enriched extract and to recombinant H11-4
(Figure 4A), rH11-1 and rH11-5 proteins. No ConA-HRP
binding was observed with protein expressed from a
rH11-4 gene construct in which the three potential
N-glycosylation sites had been altered by site-directed
mutagenesis (H11-4ΔN-Gly), indicating specific inter-
action with N-linked glycans (Figure 4A).
To identify the specific N-linked glycan structures
present on C. elegans-expressed rH11-4 protein, detailed
mass-spectrometric analysis was carried out after PNGase
F and PNGase A enzymatic release. N-glycans were
analyzed by matrix-assisted laser desorption/ionization–
time-of-flight (MALDI-TOF) mass spectrometry (MS),
as well as by collisionally activated dissociation (CAD)
on a MALDI-TOF-TOF instrument [tandem mass
spectrometry (MS/MS)]. Mixtures of N-glycans were
AB
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Figure 3 Aminopeptidase activity of C. elegans-expressed recombinant H11 proteins. (A) Aminopeptidase activity of rH11 proteins was
measured as the change in absorbance at 405 nm using L-leucine p-nitroanilide as substrate. Activity was measured at pH5.5 (striped bars) and
pH7 (blue bars) for singly expressed rH11 proteins, rH11-4 and rH11-5 co-expressed in C. elegans (rH11-4/5) and native H11-enriched extract.
500 ng total protein was added per assay. The results of triplicate assays are shown with error bars representing the standard error. (B) Reduction
in aminopeptidase (AP) activity of rH11-4/5 co-expressed proteins (striped bars) and native H11 extract (blue bars) was measured in the presence
of amastatin or bestatin, both at 10 μM final concentration. Assays were carried out in duplicate and % reduction calculated relative to pre-incubation
in buffer alone.
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spectrum of PNGase F released glycans was domi-
nated by high mannose structures (m/z 1579–2396
Man5-9GlcNAc2) (Figure 4B). This is fully consistent
with the positive Con A binding experiments. In
addition pauci-mannose type (m/z 1345–1928 Fuc0-
2Hex3-5GlcNAc2) and minor amounts of complex type
glycans (m/z 1416–2285 Fuc0-1Hex3-5GlcNAc2-4) were
identified (Figure 4B). The spectrum of PNGase A released
glycans (Figure 4C) in contrast contained only minor
amounts of high mannose type, indicative of an efficient
initial PNGase F digest. It was instead dominated by
highly fucosylated pauci-mannose type (m/z 1171–2481
Fuc0-4Hex3-6GlcNAc2). MS/MS analysis of the mo-
lecular ion of m/z 1724 (Fuc2Hex4GlcNAc2) contained
structurally informative fragment ions at m/z 1098, 853
and 648, which confirmed the presence of α1-3 and
α1-6 fucosylation, similar to native H11 extract. Thesestructures are shown in more detail in Additional file 3.
The N-glycan profiles are fully consistent with previously
published C. elegans profiles [18-20].
In addition, MS analysis showed evidence of phos-
phorylcholine (PC) modifications on rH11-4 and this
was supported by reactivity of PC TEPC-15 antibody
(Figure 4D). PNGase F released N-glycans were treated
with HF, which cleaves potential PC modifications, prior
to permethylation and MALDI-MS analysis. The HF
treated N-glycans showed an increase in abundance of
complex structures terminated with HexNAc residues
(m/z 1416–22693 Fuc0-1Hex3-6GlcNAc2-5), as shown
in Additional file 4, thus indicating probable PC substi-
tution [43]. PC on some helminth proteins has been
shown to interfere with activation of T cell and B cell re-
sponses [44,45]. We examined whether rH11 proteins
had any inhibitory effect on activation of helminth-
naive ovine peripheral blood lymphocytes using Con A
CB
A
rH11-4 rH11-4
rH11-4
N-Gly
ConA-HRP
115kDa
Nat 
H11 rH11-4
D
TEPC-15 
rH11-4
N-Gly 
115kDa
Figure 4 C. elegans-expressed rH11-4 protein is modified by N-linked glycosylation and phosphorylcholine. (A) Purified rH11-4 protein,
rH11-4 protein in which the three potential N-glycosylation sites were mutated by site directed mutagenesis (rH11-4 ΔN-Gly) and native H11-enriched
extract were separated by 4-15% SDS-PAGE, transferred to PVDF membrane and probed with HRP-labelled Con A lectin. (B and C) MALDI-TOF mass
spectrometry (MS) profiles of N-linked glycans from rH11-4 protein. N-glycans of purified rH11-4 were released from tryptic glycopeptides by digestion
with PNGase F (B) or PNGase A (C). Profiles of N-glycans are from the 50% MeCN fraction from a C18 Sep-Pak (Materials and Methods). All molecular
ions are [M + Na]+. Putative structures are based on composition, tandem MS and biosynthetic knowledge. Structures that show sugars outside of a
bracket have not been unequivocally defined. (D) Western blot of rH11-4 and rH11-4 ΔN-Gly probed with phosphorylcholine (PC) antibody TEPC-15.
Roberts et al. Veterinary Research 2013, 44:111 Page 8 of 15
http://www.veterinaryresearch.org/content/44/1/111as a polyclonal T cell activator; none was observed
as shown in the lymphocyte proliferation assays in
Additional file 5.
Vaccine trials using C. elegans-expressed H11 protein
To examine any protection afforded by rH11 protein,
six-month old lambs (7 per group) were vaccinated three
times at 3 weekly intervals with rH11 or native H11-
enriched extract and challenged at the time of the third
vaccination. In the first trial, protection using rH11-1
and rH11-4 proteins (10 μg each protein per vaccination)
was examined and a second trial tested any protection
afforded by rH11-4 and rH11-5 proteins co-expressed
in C. elegans (20 μg total protein per vaccination). In
both trials, no significant difference in FEC, wormburden or worm female:male ratio at necropsy (day 35
post-challenge infection) was observed in lambs vacci-
nated with the C. elegans-expressed rH11 proteins com-
pared to an adjuvant control group (results of trial 2
shown in Figures 5A and B and Tables 1 and 2; results
of trial 1 were very similar). Lambs vaccinated with
H. contortus native H11-enriched extract showed sig-
nificant reductions in both worm burden (93.6% reduction)
and FEC (99.9% reduction) compared to the adjuvant con-
trol group.
Antibody response to recombinant and native H11 proteins
Characterisation of the antibody responses of lambs
immunised with rH11 proteins or native H11-enriched
extract were examined to identify any quantitative or
AC D
B
Figure 5 Faecal egg output, adult worm burdens and ELISA antibody responses following vaccination with rH11-4/5 co-expressed proteins
or with native H11-enriched extract. Faecal egg count (FEC) (A) was monitored from days 14–34 post-challenge infection and adult worm burdens
(B) counted at necropsy on day 35. The mean group count from lambs vaccinated with rH11-4 /5 proteins, native H11-enriched extract or Vax Saponin
adjuvant are shown, with error bars representing the standard error of the mean. (C) ELISA OD values of antisera (1/800 dilution) reactivity to rH11-4/5
co-expressed proteins or native H11 extract following immunisation with the homologous antigen. Lambs were vaccinated on days 0, 21 and 42 and
challenged with 5000 L3 on day 42, as indicated. (D) Ig isotype responses (1/50 dilution) to native H11-enriched extract measured by ELISA.
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Table 1 Faecal egg counts (eggs per gram faeces) after challenge infection.
Sample Days post challenge infection
no. d14 d18 d21 d24 d27 d31 d34
1 0 183 2547 5265 4374 2808 3879
2 0 183 3726 6057 4347 9981 9360
Adjuvant 3 0 1080 3402 9783 7794 11628 17586
control 4 0 549 4788 10998 9405 9045 15129
5 1 51 1497 10863 5769 5400 8937
6 0 909 3834 10791 9135 18846 13374
7 0 183 3717 8307 9621 7551 9279
Mean 0.17 448.3 3358.7 8866.3 7206.4 9322.7 11077.7
SE 0.4 406.3 1053.5 2389.2 2345.0 5123.2 4594.1
8 0 0 0 39 8 48 25
9 0 0 0 1 0 2 4
Native 10 0 0 1 0 2 4 0
H11 11 0 0 2 11 17 0 29
Extract 12 0 0 1 4 7 4 6
13 0 1 0 1 0 1 0
14 0 0 0 8 20 51 26
Mean 0 0 1 9 8 16 13
SE 0 0 1 14 8 23 13
15 0 480 5319 8289 7776 6435 8289
16 0 354 2556 6966 6696 7272 9171
rH11-4/5 17 0 113 4815 12123 9504 3420 7398
18 0 122 2412 7767 4563 3699 7884
19 0 19 2016 5697 5562 3447 14724
20 0 231 3771 11862 12789 3753 9054
21 0 237 3294 12483 16335 5922 13968
Mean 0 222.3 3454.7 9312.4 9032.1 4849.7 10069.7
SE 0 156.7 1252.8 2782.8 4217.4 1636.5 2994.0
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responses as previous studies have shown a correlation
between protection and serum antibody level [42] and
protection can be conferred by passive transfer of im-
mune serum [42] or colostrum [46]. By ELISA, a peak in
antibody response was observed 7 days after the third
vaccination/challenge with native H11 extract or recom-
binant H11 protein (day 49; Figure 5C). Although reach-
ing a similar maximum level, the antibody titre rose
earlier (day 21) and was maintained at a higher level for
longer in lambs immunised with native H11 extract.
Maximum response was observed against the homolo-
gous protein used in vaccination (i.e. greater recognition
of native H11 extract with antiserum from those vacci-
nated with this extract and vice versa). This most likely
reflects the complexity of the native extract, which con-
tains a number of other proteins in addition to H11.
Antibody induced to each of these components willcontribute to the ELISA response and may explain the
earlier and more sustained antibody titre observed fol-
lowing vaccination with native H11-enriched extract.
Comparison of antibody avidity, by performing ELISAs
in the presence of increasing concentrations of KSCN,
showed slightly higher avidity of antibody from lambs
immunised with rH11-4/rH11-5 co-expressed proteins
compared to those immunised with native H11 extract
(3.2 M vs 2.7 M KSCN). The antibody response to vac-
cination with native H11-enriched extract was predom-
inantly of the IgG isotype, although IgE and to a lesser
extent IgM responses were detected at day 21 of the
trial, at the time of the second vaccination (Figure 5D).
In contrast, IgG was the only isotype detected following
vaccination with rH11 proteins, with no IgE or IgM re-
sponse identified. Using rH11-4/rH11-5 proteins on ELISA
plates, only IgG isotype was detected and, similarly, coating
ELISA plates with a purer preparation of native H11 (ConA
Table 2 Worm burdens at necropsy (day 35 post challenge).
Sample no. Males Females Total worm count
1 1750 1750 3500
2 1150 1950 3100
Adjuvant 3 1300 1000 2300
control 4 2100 1650 3750
5 1350 2100 3450
6 2500 2700 5200
7 2000 1850 3850
Mean 1735.7 1857.1 3592.9
SE 494.7 511.1 877.2
8 250 0 250
9 150 100 250
Native H11 10 150 0 150
extract 11 250 0 250
12 250 50 300
13 150 50 200
14 200 0 200
Mean 200 28.6 228.6
SE 50 39.3 48.8
15 1150 1550 2700
16 1200 1450 2650
rH11-4/5 17 3650 3400 7050
18 4500 4250 8750
19 1650 2750 4400
20 900 1600 2500
21 1800 2150 3950
Mean 2121.4 2450.0 4571.4
SE 1390.7 1068.9 2432.6
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http://www.veterinaryresearch.org/content/44/1/111binding proteins passed over peanut lectin followed by gel
filtration chromatography), no IgE nor IgM responses
were detected (Additional file 6), suggesting that these
may be directed to other components of the native
H11-enriched extract.
Antiserum from lambs vaccinated with rH11-4/5 pro-
teins or native H11-enriched extract recognised both
recombinant and native H11 proteins to a similar level
by Western blot. Using this method, most of the anti-
body response detected was to glycan moieties on rH11,
as indicated by the significantly reduced reactivity (ap-
proximately 95% reduction) to rH11-4ΔN-Gly, in which
the three predicted N-glycosylation sites were mutated
(Figure 6). The level of reduction was similar using anti-
serum to native H11 extract (Figure 6A) or rH11 protein
(Figure 6B). Mild periodate treatment of rH11 or nH11
protein similarly reduced recognition by both antisera.
ELISA showed a reduction in antibody reactivity to rH11-
4ΔN-Gly or periodate-treated recombinant H11-4/5 or
native H11 extract, but to a lesser extent than by Westernblot (45-59% reduction). Therefore vaccination with rH11
proteins or native H11-enriched extract induces a sig-
nificant antibody response to glycan or glycan-linked
epitopes.
Discussion
A major hurdle in the development of commercial vac-
cines for parasitic nematodes is the difficulty of express-
ing identified protective antigens in a recombinant form
capable of inducing protective immunity. Currently, vac-
cination studies are limited by the low amounts of native
protein that can be purified from parasite extracts, the
requirement for parasite material from infected hosts
and the cost, safety and ethical considerations of this
approach. Alternative methods of producing defined
sub-unit vaccines are urgently needed. In this study we
examined the suitability of C. elegans as an alternative
expression system for parasitic nematode vaccine candi-
dates. C. elegans is in the same nematode clade (clade
V) as many important livestock parasites and it has been
shown that some of the glycosylation pathways and
modifications in C. elegans are present in related para-
sitic species [18,19].
There is increasing interest in parasitic helminth glycans
due to their strong antigenicity and the protective poten-
tial of some glycans [47]. For example, novel tyvelose-
capped glycoproteins (TSL-1 group) are present on the
larval surface of the pig nematode Trichinella spiralis.
These are strongly antigenic and anti-TSL-1 antibodies
provide protection by expelling larvae from the intestine
[48]. In this study we focussed on H. contortus H11 ami-
nopeptidase, which is enriched in one of the most
effective vaccine preparations identified for any parasitic
nematode. Native H11 has previously been demonstrated
to be modified with an unusual and highly antigenic
Fucα(1–3) GlcNAc moiety and we showed here by
detailed MS analysis that recombinant H11 expressed in
C. elegans is modified with very similar di and tri-
fucosylated glycans to the native protein. However, the
N-glycan profile is fully consistent with that of C. elegans
and indicates some structural differences from those of
native H11-enriched extract. For example, many core
fucosylated glycans are additionally modified with gal-
actose residues and no evidence could be found for
fucosylated LacdiNAc (LDNF) and Galα1-3GalNAc struc-
tures. While antibody to LDNF glycan has been correlated
with protection following immunisation with H. contortus
ES antigens [49], no correlation was found between the
antibody response to LDNF and protection induced by
H-galGP gut complex. This could reflect differences in
glycan abundance between the antigens used [50]. As
shown here, much of the response to rH11 vaccination
is to glycan structures, similar to the response with native
H11 extract. Despite this significant anti-glycan response,
rH11-4
rH11-4
rH11-4
rH11-4
rH11-4
rH11-4
rH11-4
rH11-4
N-Gly
antiserum
periodate
antiserum
nat H11
nat H11
periodate
115kDa
antiserum
115kDa
N-Gly
Anti-rH11 Anti-rH11 Anti-rH11
Anti-rH11 Anti-rH11 Anti-rH11
antiserum antiserum
nat H11periodate
antiserum
nat H11
periodate
115kDa 115kDa
Anti-His
antibody
rH11-4
rH11-4
periodate
115kDa
A
B
C
Figure 6 Antibody reactivity to glycan epitopes on C. elegans recombinant or native H11 proteins. Western blots showing recognition of
rH11-4, rH11-4ΔN-Gly, native H11-enriched extract and native H11-enriched extract treated with mild periodate, by antibody to native H11 extract
(anti-nH11; panel A) or to rH11-4/5 proteins (anti-rH11; panel B). Reactivity of anti-His antibody confirmed equal loading of rH11-4 protein (panel C).
Proteins in addition to H11 are observed in the nH11 extract.
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observed, suggesting that the response to glycans on H11
does not contribute to protective immunity, or that the
specific protective glycan structures are not present on
rH11.
Following vaccination with rH11 proteins, a high
antibody titre was measured by ELISA and detected by
Western blot. However this level of response was short-
lived and not maintained during challenge infection. In
contrast, vaccination with native extract enriched for H11
induced an earlier antibody response that was maintained
at a high level during infection. In addition, IgE antibodywas detected in response to vaccination with native H11-
enriched extract, but not to recombinant H11 protein.
While H11 is predominant in the native extract, other
components have been identified by MS peptide analysis
(DPK and AJD, submitted). Our findings using C. elegans
suggest that the lack of protection observed with recom-
binant proteins may not be due to qualitative differences
between recombinant and native proteins, such as folding
as previously speculated, but due to differences in the
responses induced by the different protein preparations.
We suggest that the level of antibody response stimu-
lated by the recombinant proteins may not be above a
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sufficient protection. In addition, the nature of the re-
sponse, including Ig isotype, may differ between the
two groups and influence immune outcome. Vaccination
studies using recombinant forms of the H. contortus
H-gal-GP complex (rPEP-1 and rMEP isoforms) expressed
in E. coli or Pichia pastoris also induced an antibody
response of shorter duration than native H-gal-GP-
enriched extract, which may also explain the lack of
protection observed [51].
While the effects of additional vaccine doses and/or
use of alternative adjuvants, such as iscoms or other
nanoparticles, may help prolong the antibody response
[52], attempting to mimic the complexity of native pro-
tein vaccines may be key to successful recombinant
vaccines. Recent studies aimed at developing a recom-
binant vaccine against the related sheep GI nematode
T. circumcincta, demonstrated significant reductions
in FEC using a cocktail of eight recombinant proteins
[53]. It is likely that multicomponent vaccines are re-
quired for adequate protection against complex metazoan
parasites. Thus, combining vaccine candidate antigens into a
multivalent vaccine is likely to enhance the immune response
above a threshold and/or influence immune outcome.
In this study, strong antibody responses to glycan epi-
topes on C. elegans expressed rH11 and native H11 were
observed. While glycans can be strongly antigenic and
may induce protective responses, they can also detract
from a protective immune response [44] or mimick host
glycans [54], thus protecting the parasite. This is particu-
larly relevant to carbohydrates with allergenic potential
and PC modifications, which can suppress immune re-
sponses. We showed here that recombinant H11 expressed
in C. elegans is heavily glycosylated and modified by PC.
Initial findings from ovine lymphocyte activation assays
using Con A indicate that rH11 has no suppressive
effect on T cell activation and, while it is unclear what
effect rH11 has on B cell activation, high antibody titres
were generated to rH11 following immunization. The
highly fucosylated glycans on H11 could serve a bio-
logical function for the parasite, such as interaction with
lectins and/or ingested nutrients, rather than as decoys.
C. elegans mutants defective in GDP-fucose biosynthesis
are resistant to the effects of ingested bacterial and
fungal toxins [55], suggesting that fucose-containing
glycoconjugates may act as binding proteins within the
nematode gut.
It is possible that the lack of protection observed with
C. elegans-expressed rH11 proteins could indicate that
H11 is not protective. However, we showed by RNA
interference (RNAi) that reduction of H11 mRNA levels
has a detrimental effect on worm development in vivo
[56]. This suggests that knockdown of H11 affects H11
assembly and/or activity within the worm gut. Althoughit cannot be assumed that antibody induced by native
extract has a similar effect as RNAi within the parasite,
we suggest that other gut proteins in combination with
H11 may be required for protection. While functional
redundancy between H11 isoforms has been speculated
[8], in the current study three different recombinant H11
isoforms were used in vaccination trials and antibody gen-
erated cross-reacted with all isoforms. This suggests that
there is sufficient similarity for antibody to target multiple
H11 proteins.
We have shown here that the C. elegans system is
amenable to co-expression of parasite proteins and that
production of sufficient protein for protection studies is
feasible. Therefore further protection using multiple pro-
teins, including other gut enzymes or ES components,
co-expressed in C. elegans in active and post-translationally
modified forms are warranted. The outcomes will be im-
portant for progressing recombinant vaccine development
for H. contortus and other parasitic nematodes. In addition,
the use of C. elegans glycosylation mutants or site directed
mutagenesis of introduced genes can allow comparison of
glycosylated and non-glycosylated forms of proteins, which
is relevant to understanding induction of immunity and
suppressive effects of nematode infections.Additional files
Additional file 1: Expression plasmid for the H. contortus H11-4
gene in transgenic C. elegans. Grey shading, C. elegans cpl-1 promoter;
striped shading, H. contortus Hmcp-6 signal sequence; black shading,
cDNA gene fragment encoding H. contortus H11-4; hatched region, C. elegans
cpl-1 3′ UTR. A C. elegans synthetic intron (SI) was introduced to aid transgenic
expression and a 10 amino acid His tag encoding sequence was included at
the 3′ end of the cDNA to allow purification using cobalt resin.
Additional file 2: Amino acid sequence alignment of all five
identified H. contortus H11 isoforms. The transmembrane domain of
each isoform (predicted using TMHMM Server v. 2.0) is indicated in
bold type and the active site HELAH and GAMEN motifs shown in
blue. N-glycosylation sites predicted using NetNGlyc (1.0 Server) are
shown in red. Accession numbers: H11, Q10737.2; H11-1, CAB57357.1;
H11-2, CAB57358.1; H11-4, CAC39009; H11-5 KF381362.
Additional file 3: MALDI-TOF-TOF MS/MS of PNGase A released
N-glycan. MALDI-TOF-TOF MS/MS of molecular ion detected at m/z
1724 (selected from spectrum shown in Figure 4C). The horizontal arrows
on the spectra indicate losses from the molecular ion [M + Na]+ of the
designated N-glycan sequences in inset. All molecular ions are [M + Na]+.
Structures that show sugars outside of a bracket have not been unequivocally
defined.
Additional file 4: HF treated N-linked glycans from H11-4 recombinant
protein. MALDI-TOF MS of N-linked glycans (PNGase F) from H11-4
recombinant protein before (A) or after HF treatment (B). Profiles of
N-glycans are from the 50% MeCN fraction from a C18 Sep-Pak (Materials
and Methods). All molecular ions are [M + Na]+. Putative structures are based
on composition, tandem MS and biosynthetic knowledge. Structures that
show sugars outside of a bracket have not been unequivocally defined.
Additional file 5: T cell activation in the presence of rH11-1, rH11-4
and rH11-4/5. To determine whether rH11-1, rH11-4 or rH11-4/5 had
any effect on lymphocyte activation, peripheral blood mononuclear cells
from a helminth-naive lamb were cultured with 5 μg/mL of the T cell
mitogen Con A in the presence or absence of 1.25-5 μg/mL of rH11-1,
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http://www.veterinaryresearch.org/content/44/1/111rH11-4 or rH11-4/5. Recombinant proteins were added 30 min before
Con A to limit any direct binding of the recombinant proteins to Con A.
Cell proliferation was assessed by incorporation of [3H] thymidine at 72 h
and was expressed as counts per minute (CPM). No significant difference
in proliferation was observed between cultures stimulated with Con A alone
vs. cultures stimulated with Con A + rH11-1 or rH11-4 (A) or Con A + rH11-4/5
(B). Data represent mean of three replicates, with error bars representing
the standard error of the mean. Statistical analysis was performed using
Kruskal–Wallis one-way analysis of variance.
Additional file 6: Ig isotype responses to rH11-4/5 (A) and to a
purer preparation of native H11 (B) measured by ELISA. ELISA OD
values of antisera (1/50 dilution) following immunisation with native
H11-enriched extract on days 0, 21 and 42 and challenged with 5000 L3
on day 42, as indicated.
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